Scott L. Friedman

Icahn School of Medicine at Mount Sinai — United States

Medicine · Health Sciences

143h-index94.9kcitations707works11.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(338), Liver physiology and pathology(241), Kruppel-like factors research(72), Liver Disease and Transplantation(71), Hepatitis C virus research(45)

Publications702 total

Landmarks in modern hepatology: A personal perspective
Med·2026
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH
Cell Metabolism·2026· 1 citedOpen Access
Hepatic Fibrosis and Liver Cancer
Seminars in Liver Disease·2025
PDGFRß targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation
EJNMMI Radiopharmacy and Chemistry·2025Open Access
Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated Steatohepatitis
Clinical Gastroenterology and Hepatology·2025
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis
Hepatology·2025· 2 citedOpen Access
Bridging dimensions: a comparative analysis of 2D and 3D in vitro models for hepatocellular carcinoma research
Archives of Toxicology·2025
ACLY inhibition promotes tumour immunity and suppresses liver cancer
Nature·2025· 15 citedOpen Access
Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases
2025· 1 citedOpen Access
Real-world Comparison of Steatosis-Associated Fibrosis Estimator and Fibrosis-4 Scores for Assessing Metabolic Dysfunction-associated Steatotic Liver Disease-related Fibrosis in a Highly Diverse Urban Metabolic Dysfunction-associated Steatotic Liver Disease Population
Clinical Gastroenterology and Hepatology·2025
Scar-associated endothelial-stellate cellular crosstalk drives fibrosis resolution in MASH
2025· 1 citedOpen Access
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases
Journal of Hepatology·2025· 9 citedOpen Access
Identifying Environmental Factors Associated with Significant Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis
Digestive Diseases and Sciences·2025· 4 cited
Resolvin D1-mediated cellular crosstalk protects against MASH
JHEP Reports·2025· 3 citedOpen Access
Mo1597: ORAL MICROBIOME DIVERSITY AND ITS ASSOCIATION WITH LIVER FIBROSIS: INSIGHTS FROM THE NHANES 2009-2012 STUDY
Gastroenterology·2025
FRI-388 Quantitative digital pathology and AI to characterize histological phenotypes of regression in a robust mouse model of human MASH
Journal of Hepatology·2025
FRI-389 Histological phenotypes of regression in advanced liver fibrosis using quantitative digital pathology in a rodent model of cirrhotic human NASH with HCC
Journal of Hepatology·2025
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
JHEP Reports·2025· 16 citedOpen Access
Can we talk? The cryptic communications of hepatic stellate cells in lipid metabolism
Cell Metabolism·2025· 2 cited
Fat, fibrosis, and the future: navigating the maze of MASLD/MASH
Journal of Clinical Investigation·2025· 7 citedOpen Access
page 1 of 36Next →

Frequent Co-authors

Josep M. Llovet(10), Augusto Villanueva(8), Yujin Hoshida(7), Swan N. Thung(6), Vincenzo Mazzaferro(6), Derek Y. Chiang(5), Sasan Roayaie(5), Myron Schwartz(5), Jordi Bruix(5), Samuel Waxman(5), Arun J. Sanyal(4), Rohit Loomba(4), Maria Isabel Fiel(4), Brent A. Neuschwander‐Tetri(3), Mary E. Rinella(3), Virginia Hernández–Gea(3), Judit Peix(3), Philippa Newell(3), Massimo Pinzani(3), Vlad Ratziu(3)